Optimal design of pharmacokinetic-pharmacodynamic studies

Pharmacokinetics in Drug Development

Volumn 3, Issue , 2011, Pages 175-193

  Foo, Lee Kien ^a   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900176521     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-7937-7_8     Document Type: Chapter

References (37)

1. Atkinson AC. DT-Optimum Designs for Model Discrimination and Parameter Estimation. J Stat Plan Inference 2008;138:56-64
2. Atkinson AC, and Donev AN. Optimum Experimental Designs. Oxford Statistical Science Series 8, Vol. 8. Oxford: Clarendon Press 1992
3. Atkinson AC, and Fedorov VV. The Design of Experiments for Discriminating Between Two Rival Models. Biometrika 1975a; 62(1):57-70
4. Atkinson AC, and Fedorov VV. Optimal Design: Experiments for Discriminating Between Several Models. Biometrika 1975b; 62(2):289-303
5. Bogacka B et al. ICODOE. Memphis 2005
6. Cramér H. Mathematical Methods of Statistics. Princeton, NJ: Princeton University Press 1946
7. D'Argenio DZ. Incorporating Prior Parameter Uncertainty in the Design of Sampling Schedules for Pharmacokinetic Parameter Estimation Experiments. Math Biosci 1990;99(1):105-118
8. D'Argenio DZ. Optimal Sampling Times for Pharmacokinetic Experiments. J Pharmacokinet Biopharm 1981;9:739-756
9. Draper NR, and Hunter WG. Design of Experiments for Parameter Estimation in Multiresponse Situations. Biometrika 1966;53:525-533
10. Duffull SB, Graham G, Mengersen K, and Eccleston J. Evaluation of the Pre-posterior Distribution of Optimized Sampling Times for the Design of Pharmacokinetic Studies. J Biopharm Stat [in press]
11. Duffull SB, Mentré F, and Aarons L. Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine. Pharm Res 2001;18:83-89
12. Duffull S, Waterhouse T, and Eccleston J. Some Considerations on the Design of Population Pharmacokinetic Studies. J Pharmacokinet Pharmacodyn 2005;32(3-4):441-457
13. Foo L-K, McGree J, Eccleston J, and Duffull S. Comparison of Robust Criteria for D-Optimal Design. Manuscript submitted for review.
14. Foo L-K, and Duffull S. Methods of Robust Design of Nonlinear Models with an Application to Pharmacokinetics. J Biopharm Stat 2010;20(4):886-902
15. Graham G, and Aarons L. Optimum Blood Sampling Time Windows for Parameter Estimation in Population Pharmacokinetic Experiments. Stat Med 2006;25:4004-4019
16. Green B, and Duffull SB. Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study. J Pharmacokinet Pharmacodyn 2003;30(2):145-161
17. Gueorguieva I, Aarons L, Ogungbenro K, Jorga KM, Rodgers T, and Rowland M. Optimal Design for Multivariate Response Pharmacokinetic Models. J Pharmacokinet Pharmacodyn 2006;33:97-124
18. Hennig S, Waterhouse TH, Bell SC, France M, Wainwright CE, Hugh M, Charles BG, and Duffull SB. A D-Optimal Designed Population Pharmacokinetic Study of Oral Itraconazole in Adult Cystic Fibrosis Patients. Br J Clin Pharmacol 2007;63(4):438-450
19. Hoeting JA, Madigan D, Raftery AE, and Volinsky CT. Bayesian Model Averaging: A Tutorial. Stat Sci 1999;14(4):382-417
20. Hooker A, and Vicini P. Simultaneous Population Optimal Design for Pharmacokinetic-Pharmacodynamic Experiments. AAPS J 2005;7:E759-E785
21. Hooker AC, Foracchia M, Dodds MG, and Vicini P. An Evaluation of Population D-Optimal Designs Via Pharmacokinetic Simulations. Ann Biomed Eng 2003;31:98-111
22. McGree JM, Duffull SB, Eccleston JA, and Ward LC. Optimal Design for Studying Bioimpedance. Physiol Meas 2007;28:1465-1483
23. McGree JM, Eccleston JA, and Duffull SB. Compound Optimal Design Criteria for Nonlinear Models. J Biopharm Stat 2008;18(4):646-661
24. McGree JM, Duffull SB, and Eccleston JA. Simultaneous Versus Sequential Optimal Design for Pharmacokinetic-Pharmacodynamic Models with FO and FOCE Consideration. J Pharmacokinet Pharmacodyn 2009;36:101-123
25. Mentré F, Maller A, and Baccar D. Optimal Design in Random-Effects Regression Models. Biometrika 1997;84(2):429-442
26. Mentré F, Duffull S, Gueorguieva I, Hooker A, Leonov S, Ogungbenro K, and Retout S. Software for Optimal Design in Population Pharmacokinetics and Pharmacodynamics: a Comparison. PAGE 16 2007 Abstr 1179 [http://www.page- meeting.org/?abstract=1179]
27. Ogungbenro K, and Aarons L. Optimization of Sampling Windows Design for Population Pharmacokinetic Experiments. J Pharmacokinet Pharmacodyn 2008;35:465-482
28. Rao CR. Information and the Accuracy Attainable in the Estimation of Statistical Parameters. Bull Calcutta Math Soc 1945;37:81-89
29. Retout S, Duffull S, and Mentré F. Development and Implementation of the Population Fisher Information Matrix for the Evaluation of Population Pharmacokinetic Designs. Comput Methods Programs Biomed 2001;65:141-151
30. Roos JF, Kirkpatrick CM, Tett SE, McLachlan AJ, and Duffull SB. Development of a Sufficient Design for Estimation of Fluconazole Pharmacokinetics in People with HIV Infection. Br J Clin Pharmacol 2008;66:455-466
31. Sheiner LB. Learning Versus Confirming in Clinical Drug Development. Clin Pharmacol Ther 1997;61(3):275-291
32. Sheiner LB, and Beal SL. Evaluation of Methods for Estimating Population Pharmacokinetic Parameters. III. Monoexponential Model: Routine Clinical Pharmacokinetic Data. J Pharmacokinet Biopharm 1983;11(3):303-319
33. Smith K. On the Standard Deviations of Adjusted and Interpolated Values of an Observed Polynomial Function and Its Constants and the Guidance They Give Towards a Proper Choice of the Distribution of Observations. Biometrika 1918;12:1-85
34. Walter E, and Pronzato L. Optimal Experiment Design for Nonlinear Models Subject to Large Prior Uncertainties. Am J Physiol 1987;253:530-534
35. Waterhouse TH, Redmann S, Duffull SB, and Eccleston JA. Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients. J Pharmacokinet Pharmacodyn 2005;32(3-4):521-546
36. Waterhouse TH, Eccleston JA, and Duffull SB. Optimal Design Criteria for Discrimination and Estimation in Nonlinear Models. J Biopharm Stat 2009;19:386-402
37. Zhu W, and Wong WK. Optimal Treatment Allocation in Comparative Biomedical Studies. Stat Med 2000;19(5):639-648